Literature DB >> 29374836

Corticotropin-Releasing Factor (CRF) Neurocircuitry and Neuropharmacology in Alcohol Drinking.

Allyson L Schreiber1, Nicholas W Gilpin2,3.   

Abstract

Alcohol use is pervasive in the United States. In the transition from nonhazardous drinking to hazardous drinking and alcohol use disorder, neuroadaptations occur within brain reward and brain stress systems. One brain signaling system that has received much attention in animal models of excessive alcohol drinking and alcohol dependence is corticotropin-releasing factor (CRF). The CRF system is composed of CRF, the urocortins, CRF-binding protein, and two receptors - CRF type 1 and CRF type 2. This review summarizes how acute, binge, and chronic alcohol dysregulates CRF signaling in hypothalamic and extra-hypothalamic brain regions and how this dysregulation may contribute to changes in alcohol reinforcement, excessive alcohol consumption, symptoms of negative affect during withdrawal, and alcohol relapse. In addition, it summarizes clinical work examining CRF type 1 receptor antagonists in humans and discusses why the brain CRF system is still relevant in alcohol research.

Entities:  

Keywords:  Alcohol dependence; Alcohol use disorder; Binge drinking; Corticotropin-releasing factor; Urocortin

Mesh:

Substances:

Year:  2018        PMID: 29374836      PMCID: PMC6064393          DOI: 10.1007/164_2017_86

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  146 in total

1.  Paradoxical activational effects of a corticotropin-releasing factor-binding protein "ligand inhibitor" in rat brain.

Authors:  R K Chan; W W Vale; P E Sawchenko
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

2.  Do centrally administered neuropeptides access cognate receptors?: an analysis in the central corticotropin-releasing factor system.

Authors:  J C Bittencourt; P E Sawchenko
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

Review 3.  A role for corticotropin releasing factor and urocortin in behavioral responses to stressors.

Authors:  G F Koob; S C Heinrichs
Journal:  Brain Res       Date:  1999-11-27       Impact factor: 3.252

4.  Urocortin expression in the Edinger-Westphal nucleus is up-regulated by stress and corticotropin-releasing hormone deficiency.

Authors:  S C Weninger; L L Peters; J A Majzoub
Journal:  Endocrinology       Date:  2000-01       Impact factor: 4.736

5.  Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors.

Authors:  J C Bittencourt; J Vaughan; C Arias; R A Rissman; W W Vale; P E Sawchenko
Journal:  J Comp Neurol       Date:  1999-12-20       Impact factor: 3.215

6.  Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain.

Authors:  M M Sánchez; L J Young; P M Plotsky; T R Insel
Journal:  J Comp Neurol       Date:  1999-06-07       Impact factor: 3.215

7.  The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats.

Authors:  A D Lê; S Harding; W Juzytsch; J Watchus; U Shalev; Y Shaham
Journal:  Psychopharmacology (Berl)       Date:  2000-06       Impact factor: 4.530

8.  Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse.

Authors:  K Van Pett; V Viau; J C Bittencourt; R K Chan; H Y Li; C Arias; G S Prins; M Perrin; W Vale; P E Sawchenko
Journal:  J Comp Neurol       Date:  2000-12-11       Impact factor: 3.215

9.  Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.

Authors:  A W Zobel; T Nickel; H E Künzel; N Ackl; A Sonntag; M Ising; F Holsboer
Journal:  J Psychiatr Res       Date:  2000 May-Jun       Impact factor: 4.791

10.  Corticosterone delivery to the amygdala increases corticotropin-releasing factor mRNA in the central amygdaloid nucleus and anxiety-like behavior.

Authors:  J D Shepard; K W Barron; D A Myers
Journal:  Brain Res       Date:  2000-04-10       Impact factor: 3.252

View more
  9 in total

Review 1.  Vasopressin and alcohol: a multifaceted relationship.

Authors:  Kathryn M Harper; Darin J Knapp; Hugh E Criswell; George R Breese
Journal:  Psychopharmacology (Berl)       Date:  2018-11-03       Impact factor: 4.530

Review 2.  Amygdala, neuropeptides, and chronic pain-related affective behaviors.

Authors:  Volker Neugebauer; Mariacristina Mazzitelli; Bryce Cragg; Guangchen Ji; Edita Navratilova; Frank Porreca
Journal:  Neuropharmacology       Date:  2020-03-15       Impact factor: 5.250

Review 3.  A Rationale for Allopregnanolone Treatment of Alcohol Use Disorders: Basic and Clinical Studies.

Authors:  A Leslie Morrow; Giorgia Boero; Patrizia Porcu
Journal:  Alcohol Clin Exp Res       Date:  2019-12-17       Impact factor: 3.455

Review 4.  Role of corticotropin-releasing factor in alcohol and nicotine addiction.

Authors:  Sierra Simpson; Kokila Shankar; Adam Kimbrough; Olivier George
Journal:  Brain Res       Date:  2020-04-21       Impact factor: 3.252

5.  Predator odor stress blunts alcohol conditioned aversion.

Authors:  Allyson L Schreiber; M Adrienne McGinn; Scott Edwards; Nicholas W Gilpin
Journal:  Neuropharmacology       Date:  2018-10-15       Impact factor: 5.250

6.  Neurobiological aspects of pain in the context of alcohol use disorder.

Authors:  Jessica A Cucinello-Ragland; Scott Edwards
Journal:  Int Rev Neurobiol       Date:  2020-10-06       Impact factor: 3.230

Review 7.  Corticotropin Releasing Factor Binding Protein as a Novel Target to Restore Brain Homeostasis: Lessons Learned From Alcohol Use Disorder Research.

Authors:  Dallece E Curley; Ashley E Webb; Douglas J Sheffler; Carolina L Haass-Koffler
Journal:  Front Behav Neurosci       Date:  2021-11-29       Impact factor: 3.558

8.  Cell-type specific changes in PKC-delta neurons of the central amygdala during alcohol withdrawal.

Authors:  Robert O Messing; R Dayne Mayfield; Geoffrey A Dilly; Cory W Kittleman; Tony M Kerr
Journal:  Transl Psychiatry       Date:  2022-07-20       Impact factor: 7.989

Review 9.  Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review.

Authors:  Pascal Valentin Fischler; Michael Soyka; Erich Seifritz; Jochen Mutschler
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.